Hill A - Search Results

1

Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment.

Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Cohn J, et al. Among authors: hill a. Curr Opin HIV AIDS. 2015 Sep;10(5):369-73. doi: 10.1097/COH.0000000000000180. Curr Opin HIV AIDS. 2015. PMID: 26185920 Review.

2

Optimizing HIV treatment.

Hill A. Hill A. Curr Opin HIV AIDS. 2013 Jan;8(1):34-40. doi: 10.1097/COH.0b013e32835b7f28. Curr Opin HIV AIDS. 2013. PMID: 23143139 Review.

3

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Hill A, et al. Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6. Clin Infect Dis. 2014. PMID: 24399087 Free PMC article.

4

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. van de Ven N, et al. Among authors: hill a. Hepatology. 2015 Apr;61(4):1174-82. doi: 10.1002/hep.27641. Epub 2015 Feb 9. Hepatology. 2015. PMID: 25482139 Free PMC article.

5

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.

Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Simmons B, et al. Among authors: hill a. Clin Infect Dis. 2015 Sep 1;61(5):730-40. doi: 10.1093/cid/civ396. Epub 2015 May 17. Clin Infect Dis. 2015. PMID: 25987643 Free PMC article. Review.

6

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Simmons B, et al. Among authors: hill a. Clin Infect Dis. 2016 Mar 15;62(6):683-694. doi: 10.1093/cid/civ948. Epub 2016 Jan 19. Clin Infect Dis. 2016. PMID: 26787172 Free PMC article. Review.

7

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries.

Hill A, Gotham D, Cooke G, Bhagani S, Andrieux-Meyer I, Cohn J, Fortunak J. Hill A, et al. J Virus Erad. 2015 Apr 1;1(2):103-10. doi: 10.1016/S2055-6640(20)30484-2. J Virus Erad. 2015. PMID: 27482399 Free PMC article.

8

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.

Gotham D, Hill A, Pozniak AL. Gotham D, et al. Among authors: hill a. Curr Opin HIV AIDS. 2017 Jul;12(4):324-333. doi: 10.1097/COH.0000000000000379. Curr Opin HIV AIDS. 2017. PMID: 28403027 Review.

9

Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication.

Shah S, Hill A. Shah S, et al. Among authors: hill a. Curr Opin HIV AIDS. 2021 Mar 1;16(2):106-114. doi: 10.1097/COH.0000000000000671. Curr Opin HIV AIDS. 2021. PMID: 33625041 Review.

10

Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

Hill A, Miralles D, Vangeneugden T, Lefebvre E. Hill A, et al. AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593. AIDS. 2007. PMID: 17630565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,538 results

Search Page

Filters